Lupin launches Apriso generic equivalent in US market

Pharma major Lupin Limited announced that it had launched an authorised generic version of Bausch Health’s Apriso (Mesalamine extended-release capsules 0.375 gm) in US Market.

The authorised generic version of Mesalamine extended-release capsules 0.375 gm is indicated for the maintenance of remission of ulcerative colitis in patients of 18 years of age and older.

As per IMS Health and Quintiles (IQVIA) moving annual total March 2020 data, Mesalamine extended-release capsules 0.375 gm, RLD: Apriso had annual sales of around US$ 290 million in US.

Lupin is an innovation-led transnational pharmaceutical company, headquartered in Mumbai (India). The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in various markets.

At 3 pm on Tuesday, the stock was trading at Rs 837.05, down by 2.34 per cent or Rs 20.05 per share. The 52-week high is recorded at Rs 906.35 and the 52-week low is Rs 505 on BSE.